Abstract
Objective
HIV-associated CNS dysfunction is a significant problem among people with HIV (PWH), who now live longer due to viral suppression from combined anti-retroviral therapy (ART). Over the course of infection, HIV generates toxic viral proteins and induces inflammatory cytokines that have toxic effects on neurons in the CNS. Among these viral proteins, HIV Nef has been found in neurons of postmortem brain specimens from PWH. However, the source of Nef and its impact on neuronal cell homeostasis are still elusive.
Methods and results
Here, in using a simian immunodeficiency virus (SIV) infected rhesus macaque model of neuroHIV, we find SIV Nef reactivity in the frontal cortex, hippocampus and cerebellum of SIV-infected animals using immunohistochemistry (IHC). Interestingly, SIV-infected macaques treated with ART also showed frequent Nef positive cells in the cerebellum and hippocampus. Using dual quantitative RNAscope and IHC, we observed cells that were positive for Nef, but were not for SIV RNA, suggesting that Nef protein is present in cells that are not actively infected with SIV. Using cell specific markers, we observed Nef protein in microglia/macrophages and astrocytes. Importantly, we also identified a number of NeuN-positive neurons, which are not permissive to SIV infection, but contained Nef protein. Further characterization of Nef-positive neurons showed caspase 3 activation, indicating late stage apoptosis in the CNS neurons.
Conclusions
Our results suggest that regardless of ART status, Nef is expressed in the brain of SIV infected macaques and may contribute to neurological complications seen in PWH.
Introduction
Human immunodeficiency virus (HIV) infection has transitioned from a rapidly-progressing, fatal disease to a chronic infection with the intervention of combined antiretroviral therapy (ART) [1, 2]. ART successfully suppresses virus in the plasma and effectively increases the life expectancy of people with HIV (PWH) [3, 4]. Despite successful therapy, ART has limited penetrance in certain organs, such as the brain, leading to the formation of viral reservoirs and development of chronic neuroinflammation and neurological disorders [5]. In the pre-ART era, HIV-associated neurocognitive disorders were severe, since the onset of ART more mild forms predominate [6]. Despite suppression of viral replication, persistent neuroinflammation continues to perturb CNS homeostasis [7]. Although many studies have investigated HIV-associated neurological dysfunction, the molecular pathways where HIV viral proteins contribute to neurological impairment over the course of HIV infection are not fully understood.
The accessory Negative Regulatory Factor (Nef) gene is encoded by HIV-1, HIV-2 and the simian immunodeficiency virus (SIV) genomes [8]. HIV Nef is a 27–35 kDa protein expressed in the early stages of the viral life cycle and is the first viral protein produced in HIV-infected cells [8, 9]. NMR structural analysis shows that HIV Nef is composed of four major regions: a myristoylated N-terminal anchor domain, a proline-rich region, a conserved globular core structure, and a C-terminal flexible loop [8, 10]. The functional domains of HIV Nef act post-translationally to decrease the cell-surface expression of CD4, downregulate MHC-1 expression, modulate TCR signaling, increase HIV replication, and increase viral infectivity [11, 12]. In vitro studies indicate that Nef expression modulates the activation of the transcription factor NF-κB and IL-2 expression, implicating Nef in regulation of immune function [13]. Nef was initially considered an inhibitor of viral genome transcription [14], but studies have since shown that the Nef gene is crucial for maintenance of a robust, high viral production and is implicated in promoting disease progression to acquired immune deficiency syndrome (AIDS) [15]. Nef also increases the infectivity of HIV virions, as HIV-1 particles produced in the presence of Nef can be up to ten times more infectious than in the absence of Nef gene [16]. Exposure of human glial cells and neurons to HIV Nef demonstrated a neurotoxic effect to CNS resident cells [17], likely through an indirect effect of IP-10 or quinolinic acid [18]. HIV Nef deletion or mutation can diminish the neurotropism of HIV suggesting that Nef may play a role in viral seeding into the CNS [19]. Furthermore, rodent studies revealed that HIV Nef induces neurocognitive impairments in rats [20, 21]. Brain autopsy samples of PWH revealed that Nef was found in both macrophages and astrocytes. In addition, Nef-positive astrocytes were detected in six out of seven specimens from PWH who had moderate to severe cognitive impairment [22]. Interestingly, Nef was also found in frontal lobe neurons of patients with HIV associated dementia [23]. More interestingly, Nef expression in astrocytes associated with neuroinflammation causing neuronal damage and inducing spatial and recognition memory deficits [19, 21, 24, 25].
The role of HIV Nef in the perturbation of neurological impairment is not fully understood. Even in the presence of ART, neurocognitive deficits, including impairments in attention, memory processing and retrieval, are present in PWH. Here, we utilized a well-established SIV infection rhesus macaque model to further study and characterize Nef expression in the brain. Our results suggest that regardless of ART status, Nef is expressed in the brain of SIV infected macaques. In addition, by combining the state of the art RNAscope with IHC, we showed that Nef detection was not limited to the cells actively replicating the virus. Moreover, cell type specific staining revealed that in addition to astrocytes and Iba-1 positive microglia and macrophages, Nef was also present in neurons and its presence was associated with apoptosis. Altogether, our results suggest that Nef may be a formidable contributor of neurological impairment seen in PWH.
Results
Nef is expressed in the brain regions of SIV infected macaques
Tissue sections of frontal cortex, hippocampus and cerebellum from uninfected (SIV-, n = 3), SIV-infected animals with encephalitis (SIVE, n = 3), SIV-infected animals without encephalitis (SIV+ No ART, n = 3), and SIV-infected animals treated with ART (SIV+ART+, n = 3) were used to detect SIV Nef protein in vivo through immunohistochemistry. Viral, drug, and zoological information of animals used in the study are provided in Table 1.
Table 1. Viral, drug, and zoological information of animals used in the study.
Animal No. | Infection Status | CD8 Depletion | Survival (Days) | Age (years) | Term. Viral Load (Log10) | Brain pathology |
---|---|---|---|---|---|---|
C01 | SIV- | N/A | N/A | 3.28 | N/A | N/A |
C02 | SIV- | N/A | N/A | 3.41 | N/A | N/A |
C03 | SIV- | N/A | N/A | 2.27 | N/A | N/A |
A01 | SIV+ | Depleted | 55 | 7.3 | 7.83 | SIVE |
A02 | SIV+ | Depleted | 89 | 10.4 | 7.71 | SIVE |
A03 | SIV+ | Depleted | 77 | 5.8 | 8.54 | SIVE |
A04 | SIV+ | Depleted | 174 | 10.8 | 7.28 | AIDS no E |
A05 | SIV+ | Depleted | 168 | 4.3 | 5.87 | AIDS no E |
A06 | SIV+ | Depleted | 106 | 4.5 | 7.69 | AIDS no E |
A07 | SIV+ART+ | Depleted | 120 | 6.2 | 2.34 | Normal |
A08 | SIV+ART+ | Depleted | 118 | 6.7 | 2.66 | Normal |
A09 | SIV+ART+ | Depleted | 118 | 6.1 | 2.66 | Normal |
N/A = Not Applicable, SIV- = Uninfected, SIV+ = SIV Infected, ART+ = ART treated, Term. = Terminal, SIVE = SIV Encephalitis, AIDS no E = Non-encephalitic
As expected, while SIV- (uninfected) tissues had no visible staining, SIV Nef staining was evident in the frontal cortex of animals with SIVE (Fig 1 and S1 Fig in S1 File). Interestingly, SIV Nef was very limited in cells from frontal cortex of SIV+ no ART and SIV+ART+ macaques (Fig 1A and 1B, S1 Fig in S1 File). On the other hand, hippocampal areas of SIVE animals showed lesions with high density of Nef staining and SIV+ no ART animals showed individually Nef positive cells. Interestingly, hippocampal regions of SIV+ART+ animals also showed Nef+ cells (Fig 1A and 1C, S2 Fig in S1 File). Cerebellar regions of SIV+ no ART and SIV+ART+ showed Nef+ cells in the molecular and Purkinje cell layers (Fig 1A and 1D, S3 Fig in S1 File). Nef positive lesions were found in the molecular layer and white matter of folium of the cerebellum of SIVE+ macaques. The SIVE animals were utilized as controls for active viral replication. For quantification purposes, and due to the current clinical presentation of HIV infection where encephalitis is rare, we did not include the lesions seen in SIVE in quantitative analysis and there was no significant difference between the number of Nef+ cells in SIV+ no ART and SIV+ ART+ in three different brain regions analyzed. These results suggest that SIV Nef is still expressed in the brain of SIV infected animals despite ART and reduced plasma viral loads.
Fig 1. Immunohistochemical staining to detect SIV Nef in different brain sections of SIV-infected macaques.
A. Representative images from paraffin embedded SIV-infected macaques brain tissue sections: frontal cortex, hippocampus and cerebellum in SIV+ ART +, SIV+ no ART and SIVE (no ART) were serial sectioned and stained for routine histological analysis and stained for SIV Nef. Representative images were taken at 20X magnification with a Keyence BZ-X700 microscope. B—D. Nef positive cells per mm2 of tissues from frontal cortex, hippocampus and cerebellum were quantified using BZ-X analyzer software (Keyence). (n = 3/per group). Five images were taken per condition per tissue. The average number per group was used for further statistical analysis. Comparison of means was determined by T-test. SIV+ ART+: SIV infected, receiving ART. SIV+ no ART: SIV infected, untreated, and SIVE: SIV infected with encephalitis. Scale bar represent 10 μM.
Cell type-specific Nef expression in hippocampus
SIV Nef protein co-localization with cell type specific markers was achieved through a Multiplexing immunofluorescent approach. Hippocampal regions of SIVE, SIV+ no ART, and SIV+ART+ animal cohorts were co-stained for GFAP, Iba-1 and SIV Nef (Fig 2, and S4 Fig in S1 File). Interestingly, hippocampal sections of SIV+ART+ animals showed SIV Nef+ cells that were negative for both GFAP and Iba-1 (Fig 2A, denoted by white arrows). The percent of Nef+GFAP+ cells was significantly different among SIVE (~8%), SIV+ no ART (~1.5%), and SIV+ ART + (~0.5%) animals (Fig 2B). Post-hoc analysis showed significantly less Nef+ GFAP+ cells in SIV+ no ART animals compared to SIVE and in SIV+ART+ compared to SIVE animals (P = 0.0084 and 0.0042). There was no significant difference between SIV+ no ART and SIV+ ART+ animals for Nef expression in GFAP+ cells. SIV Nef and Iba-1 overlap was also quantified (Fig 2C, denoted by yellow arrow). The percent Nef+Iba1+ cells were significantly different between SIVE (~19%), SIV+ no ART (~5%) and SIV+ART+ animals (~1%) (Fig 2C). Post-hoc analysis showed significantly less Nef+ Iba1+ cells in SIVE+ animals compared to SIV+ no ART and SIV+ART+ animals (P = 0.0006 and 0.0002). There was no significant difference between SIV+ no ART and SIV+ ART + animals for Nef expression in Iba-1 cells.
Fig 2. Cell type-specific Nef expression in hippocampus sections from SIV infected macaques.
A. Paraffin embedded SIV-infected macaques brain hippocampus region were serial sectioned and stained for cells specific biomarkers GFAP (red), IBA-1 (pink) and Nef (green) using 4 color opal multiplex immunohistochemical assay staining (Perkin Elmer). Representative images were taken at 20X magnification with a Keyence BZ-X700 microscope (n = 3/ per group). B -C. Quantification of number of Nef+ cells within GFAP + cells (B) and Iba-1+ cells (C) per mm 2. Five images were taken per condition per tissue with 20x magnification. The average number per group was used for further statistical analysis. Comparison of means was determined by one-way ANOVA, followed by post-hoc Tukey HSD test **P<0.05, ***P<0.001. White Arrows: Nef+/GFAP-/ IBA-1- cells. Yellow arrows: Nef+/ IBA+ cells. Grey arrow with tail: NEF+/GFAP+ cells. Scale bar represent 10 μM.
Nef expression is not limited to the SIV RNA positive cells in hippocampus and cerebellum of SIV-infected animals
In order to investigate if SIV Nef expression was limited to the SIV-infected cells, dual RNAscope and immunohistochemistry was performed to detect SIV viral RNA and SIV Nef protein in cerebellar and hippocampal regions of SIVE, SIV+ no ART, and SIV+ART+ groups. Interestingly, a population of SIV RNA- and Nef+ cells were observed in the hippocampus and cerebellum of SIVE and SIV+ no ART (Fig 3A, orange arrows, S5 and S6 Figs in S1 File). Quantification analysis of Nef+ SIV RNA- cells in hippocampus and cerebellum (Fig 3C and 3E) and RNA+ cells in hippocampus and cerebellum (Fig 3B and 3D) were also performed. Interestingly, while RNAscope revealed a significant decrease in SIV RNA expression in SIV+ART+ animals compared to SIV+ no ART, SIV RNA- Nef+ cells were undistinguishable. In order to further analyze if SIV RNA- Nef+ cells were neuronal phenotype, we also performed co-immunostaining of Nef protein with neuronal marker Neu-N. Hippocampal tissue sections were co-stained with SIV Nef and Neu-N, to determine possible overlap of Nef with neurons (Fig 4A and S7 Fig in S1 File). The observed colocalization of NeuN and Nef was evident in the perinuclear area in SIV+ART+, SIV+ no ART, and SIVE animals, suggesting the presence of Nef protein in neurons which are known to be not susceptible for SIV infection. Quantification of Nef+ and Neu-N+ cells suggested that co-expression of both proteins was about 1%, 0.8% and 0.4% in SIVE, SIV+ no ART and SIV+ART+ respectively (Fig 4B). Interestingly, while there was no significant difference between SIVE and SIV+ no ART, Nef+ neurons were significantly higher in SIV+ no ART group compared to the SIV+ ART+ animals and in SIVE group compared to SIV+ ART+ animals (P < 0.002).
Fig 3. Nef + SIV RNA- cells are detected in different brain regions of SIV-infected animals.
A. SIV RNA was visualized with RNAscope (Red) and Nef protein (Brown) markers by immunohistochemistry in the hippocampus and cerebellum of SIV-infected animals: SIV+ ART+, SIV+ no ART, and SIVE. Representative images were taken at 20X magnification with a Keyence BZ-X700 microscope. Five images were taken per condition per tissue and the average number per group was used for analysis. (n = 3/per group). B and D. Quantification analysis of SIV RNA+ cells in hippocampus and cerebellum region per mm2. C and E. Quantification analysis of number of Nef+/RNA- cells in the hippocampus and cerebellum region per mm2 using BZ-X analyzer software (Keyence). Yellow arrow: SIV RNA + and orange arrow: SIV RNA—and Nef+ cells. Scale bar represent 10 μM.
Fig 4. Detection of Nef in neurons from hippocampus of SIV- infected macaques.
A. Hippocampus regions from paraffin embedded SIV-infected macaques brain samples were serial sectioned and stained for Neu-N (pink) and Nef (green) using opal multiplex immunohistochemical assay staining. Representative images were taken at 20X magnification with a Keyence BZ-X700 microscope. (n = 3/ per group). B. Quantification analysis of number of Nef+ within NeuN + cells in hippocampus region per mm2, five images were taken per condition per tissue and the average number per group was used (n = 3). Comparisons of means for significance was determined with T-test. Scale bar represent 10 μM. (P < 0.002).
Neuronal Nef is associated with cleaved caspase-3 induction in hippocampus of SIV-infected animals
In order to characterize neuroapoptosis with SIV infection in the brain and possible neuronal Nef association with neurotoxicity, we utilized the multiplex immunofluorescence to stain for Neu-N, cleaved caspase 3 and Nef protein (Fig 5 and S8 Fig in S1 File). Interestingly, hippocampal regions of SIVE, SIV+ no ART and SIV+ ART+ animals showed Nef+ lesions and Nef+ NeuN+ neurons that colocalized with cleaved caspase 3. The total number of cells that were positive for cleaved caspase 3 were determined per mm2. The percent of cleaved caspase 3 positive cells was significantly higher in SIV+ no ART (~12%) than SIV+ART+ (~ 2%) (P = 0.0001) (Fig 5B). Further quantification suggested that there was a significant difference in percent of cleaved caspase 3 within NeuN+ and Nef- cells between SIV+ no ART (~4%) and SIV+ART+ (~0.5%) (P <0.0001) (Fig 5C). The percentage of cleaved caspase 3 within Nef+ cells were also quantified. Approximately 6% and 1% of Nef + cells were positive for cleaved caspase 3 in SIV+ no ART and SIV+ ART+, respectively (P = 0.0002) (Fig 5D). Percentage of cleaved caspase 3 within Nef+ and NeuN+ cells were analyzed and approximately 7.6% and 1% of NeuN+ and Nef+ cells were also positive for cleaved caspase 3 in SIV+ no ART and SIV+ ART+ respectively (P< 0.0001) (Fig 5E). Further quantification analysis showed that 4% and 1% of cells were cleaved caspase 3+ and Nef–in SIV+ no ART and SIV+ ART+ groups (P<0.0001) (Fig 5F). Lesions seen in SIVE animals were not considered in quantification analysis due to the extensive neuronal loss at lesion sites. While neurons are not directly infected with the virus, they appear to acquire Nef protein and show proteolytic activation of late phase caspase 3 and induction of apoptosis.
Fig 5. Multiplex analyses of Nef and cleaved caspase-3 expression in neurons.
A. Hippocampus regions from SIV-infected macaques brain samples were serial sectioned and stained for cells specific biomarkers NeuN (pink), Cleaved caspase 3 (Red) and Nef (green) using 4 color opal multiplex immunohistochemical assay staining. (Perkin Elmer). Representative images were taken at 20X magnification with a Keyence BZ-X700 microscope. (n = 3 per group). B. Quantification analysis of number of cleaved caspase 3 positive cells per mm2. C. Quantification analysis of number of cleaved caspase 3 within NeuN+ and Nef- cells per mm2. D. Quantification analysis of number of % of cleaved caspase 3+ cells within Nef+ cells in the hippocampus region. E. Quantification analysis of number of cleaved caspase 3+ cells within Nef + and NeuN + cells in the hippocampus region. F. Quantification analysis of number of cleaved caspase 3+ cells within Nef—cells. Comparison of means was determined by T-test (***P<0.005, ****P<0.0001). Scale bar represent 10 μM.
Discussion
HIV-1 was initially thought to target immune cells in the periphery including T lymphocytes, monocytes/macrophages, and dendritic cells. Although the mechanisms of HIV infiltration into the brain remain debatable, several studies have illustrated that CNS cells such as perivascular macrophages, microglia, and astrocytes are also susceptible to infection [26–29]. Microglia and perivascular macrophages serve as persistence and latent viral reservoirs, supporting productive HIV-1 infection [26–29]. Neurons are not infected with HIV, however, the virus targets neurons through viral proteins, such as Tat, gp120, and Vpr. Effects of HIV-1 Tat and gp120 expression in the brain have been extensively studied [30–32]. HIV Tat disrupts blood-brain barrier integrity and alters neuronal intrinsic excitability, affects calcium dysregulation, causes astrocytosis, and leads to the subsequent death of neurons [33]. Gp120 causes neuronal apoptosis, increases inflammatory cytokines, increases oxidative stress, and disrupts the blood-brain barrier [34]. Both Tat and gp120 appear to be well characterized causing serious neurotoxic consequences in HIV-1 infected brains [30, 33–35]. Despite gp120 and Tat and other viral proteins, little is known about the characteristics and potential impact of HIV-1 Nef in the development of HIV-associated neurological disorders. Accumulating evidence suggest that Nef is an important contributor to the development of HIV associated neurological disorders. It can cause significant decrease in metabolic activities and increase cell death rates [17]. In vivo expression of Nef leads to neuronal loss and neuroinflammatory response, including upregulation of IP-10. Interestingly, increased expression of IP-10 has been detected in the brains of HIV individuals with severe cognitive deficits [20]. Also, Nef induces the recruitment of peripheral immune cells such as macrophages into the CNS resulting in an increase in neuronal apoptosis and a neuroinflammatory profile [20, 21]. In our work, we have elucidated the expression of Nef protein in different brain regions of SIV-infected animals and correlated cell-type-specific Nef expression with neurotoxicity. The results of our study demonstrate that Nef is expressed in different brain regions; frontal cortex, hippocampus, and cerebellum. To our knowledge, this is the first in vivo study demonstrating Nef expression and characterizing different cell types expressing Nef in the brain of SIV-infected macaques. Furthermore, the data presented here demonstrate that neurons within the hippocampus are positive for Nef in macaques on ART indicating that despite ART therapy, Nef might be still present in the different cell types, including neurons in the brain. Our RNAscope analyses further revealed that within the hippocampus and cerebellum there are cells that are actively infected with SIV as evidenced by the detection of viral RNA in these regions and cells in the proximity of infected cells that are positive for Nef protein in which SIV RNA was not detected. These data suggest that Nef protein is most likely transported from the infected cells to the uninfected neuronal cells. One inherent limitation of this study is the sample size being small (n = 3 per group). Relatively small number of animals used in this study is due to the limited availability of large-scale primate tissues and its focus on the presence of HIV-1 Nef in different cell types in different brain regions of animals with different disease stages. In addition, our IHC studies with Iba-1 marker suggested that a significant number of Iba-1+ cells are also positive for Nef. Due to the shared lineage of microglia and macrophage/monocytes, Iba-1 only represents the overall lymphoid cells and does not necessarily suggest the lymphoid cell types. Whether Nef is preferentially expressed in certain lymphoid cells at different stage of the HIV CNS disease remains to be elucidated.
Several in vivo studies suggest that Nef protein can be transferred from infected to uninfected cells and is considered as circulating viral factor, contributing to HIV pathogenesis. Using CD4.Nef.GFP transgenic mice and chimeric SIV infected macaques, it was shown that intracellular Nef was transferred from T cells to the endothelium [36]. In addition, Nef protein was present in extracellular vesicles (EVs) isolated from SIV infected macaques and was able to transfer Nef into other recipient cells [37]. Furthermore, it was demonstrated that Nef was present in the sera from 27 out of 32 HIV-1 patients [38]. Several other independent groups have also detected HIV-Nef protein in EVs isolated from the plasma of HIV-infected patients [39–42]. Other studies demonstrated that intracellular Nef was detected in peripheral blood mononuclear cells (PBMCs) in HIV infected patients with and without antiretroviral therapy [36] and was detected in uninfected B cells of lymphoid follicles of infected individuals [43].
Several decades ago, in vitro and in vivo studies illustrated that cell-type-specific proteins are found in other cell types. [44, 45]. These observations were studied in greater depth, leading to the discovery of many mechanisms by which proteins traffic between cells. These include trogocytosis, an active protein transport mechanism with tight contacts between cells [46], and formation of nanotubes that extend between neighboring cells as 50–200 nm long F actin containing protrusions from the plasma membrane of one cell to another cells [47]. Another mechanism in which proteins and other biological material transferred between cells is the exosomal protein transport [48]. Exosomes are conserved intercellular communication strategies between cells in which they exchange materials such as nucleic acids, proteins, and lipids and are released from multivesicular bodies (MVBs) [48]. More recently, exosomes in CNS have gained attention since these vesicles serve as one means of physiologic and pathologic cargo transfer between neurons and glial cells. Oligodendrocytes and astrocytes have shown to release neuroprotective exosomes to support neuronal metabolism and homeostasis [49–52]. In addition to neuroprotection, exosomes are also known to transfer pathological proteins between cells, enhancing neurodegenerative disorders as evident by the neuronal release of α-Syn-containing exosomes that are uptaken by glial cells [53] and the spread of β-amyloid peptide and tau protein to the extracellular space [54–56]. HIV Nef may also utilize multiple mechanisms to get transported from infected to the uninfected cells. Indeed, Nef was shown to be transferred to the bystander T cells by trogocytosis [57]. Nef is also shown to induce TNT formation [58, 59], and can be transferred from infected macrophages to the B lymphocytes [60], macrophages to T cells [59], Nef-expressing T cells to hepatocytic cells [61], and T cells and monocytes to human coronary arterial endothelial cells [36]. Accumulating evidence suggests that Nef -associated EVs from Nef expressing donor cells have damaging effects on recipient cells [37, 41, 62–66]. We also recently reported that Nef is released from infected astrocytes in association with EVs that are taken up by primary neurons [67]. These Nef carrying EVs suppressed functional neuronal action potential as it was assessed by multi-electrode array studies and caused neurotoxicity. Here, in line with the previous studies, our data suggest that the presence of Nef in neurons is associated with induction of cleaved caspase 3, indicative of late apoptosis and neurotoxicity.
HIV infection in the brain manifests itself at different levels in neuronal activities leading to a wide spectrum of neurological disorders ranging from mild cognitive deficiencies to motor functions and behavior abnormalities. PWH receiving ART have reduced risk of neurocognitive impairment but still are at a greater incidence of neurological impairments compared to the uninfected population [68]. Overall in this study, we characterized Nef expression in different brain regions of SIV-infected macaques. Interestingly, our data suggest that Nef is expressed in the hippocampus and cerebellum of SIV-infected animals despite treatment with ART. We further shed light on the different cell types positive for Nef protein including neurons that are undergoing apoptosis in ART-treated animals. Expression and secretion of viral proteins are proportional to viral load [69] but are not necessarily eliminated by ART, as illustrated with Nef expression and its association with apoptosis. Overall, our study highlights the possible role of HIV secretory proteins including Nef in HIV CNS disease seen in PWH.
Material and methods
Animals used in the study and ethical statement
Twelve male, Indian rhesus macaques (Macaca mulatta) were used in this study (Table 1). Three rhesus macaques (C01-C03, SIV-) served as uninfected controls. Nine animals (A01-A09, SIV+) were injected intravenously with SIVmac251 viral swarm (5ng p27; Tulane National Primate Research Center’s (TNPRC) Viral Core). A subcutaneously a dose of 5mg/kg of anti-CD8 antibody was administered at 6 days post-infection (dpi) and 5mg/kg of the antibody intravenously at 8 and 12 dpi (Nonhuman Primate Reagent Resource) for CD8 depletion. The SIV-infected (SIV+) animals were sacrificed according to humane endpoints consistent with the recommendations of the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. The development of simian AIDS was determined post-mortem by the presence of Pneumocysti carinii-associated interstitial pneumonia, Mycobacterium avium-associated granulomatous enteritis, hepatitis, lymphadenitis, and/ or adenovirus infection of surface enterocytes in both small and large intestines. SIVE was defined by the presence of multinucleated giant cells, accumulation of macrophages in the CNS, and productive viral infection [51]. It is important to note that SIVE animals did not receive ART. Three animals (A10-A12, SIV+ART) received a triple ART regimen: Raltegravir (22 mg/kg oral twice daily, Merck), Tenofovir (30 mg/kg subcutaneous once daily, Gilead), and Emtricitabine (10 mg/kg subcutaneous once daily, Gilead) at 21 dpi until the timed sacrificed at 118–120 dpi. Animals were anesthetized with ketamine-HCL and euthanized by intravenous pentobarbital overdose. Animals used in the study were housed at the TNPRC. All animals used in this study were handled in strict accordance with American Association for Accreditation of Laboratory Animal Care with the approval of the Institutional Animal Care and Use Committee of Tulane University. Monkeys were housed in pairs to promote the psychological well-being of nonhuman primates. Enrichment included manipulable items in cage (durable and destructible objects), perches or swings, various food supplements (fruit, vegetables, primate treats), foraging or task-oriented feeding methods and human interaction with caretakers and research staff as dictated by The United States Animal Welfare Act. Enrichment devices are rotated on a weekly basis and include toys, mirrors, radios, TV/VCRs, foraging boards, and a variety of complex foraging devices. Animals were fed a normal monkey chow. Animal care staff monitored the health and well-being of the animals on a daily basis with physical examinations performed weekly. All possible measures were taken to minimize discomfort of the animals. Anesthesia and analgesics were used and administered under the direction of a licensed veterinarian. All procedures were performed under ketamine or telazol anesthesia. Analgesics such as buprenorphine and lidocaine were used preemptively and following each potentially painful procedure. All animals were euthanized according to humane endpoints consistent with the recommendations of the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. Endpoint criteria for euthanasia included the following: weight loss >15% in 2 weeks or >30% in 2 months, documented opportunistic infection, persistent anorexia >3 days without explicable cause, severe, intractable diarrhea, progressive neurologic signs, significant cardiac and/or pulmonary signs or any other serious illness.
Immunohistochemistry (IHC)
For histologic examination, frontal cortex, hippocampus and cerebellum regions of brains from uninfected animals (SIV-), SIV-infected animals with encephalitis, without receiving ART (SIVE), SIV-infected animals without encephalitis (SIV+), and SIV-infected animals treated with ART (SIV+ART+) were fixed in 10% formalin and embedded in paraffin. Paraffin-embedded tissues were cut in five-micron thick sections and analyzed for protein expression by IHC. Sections were deparaffinized in xylene and hydrated in 100%, 90%, and 75% of ethanol. Sections were heat-treated at 95°C for 20 min in an antigen unmasking solution (Vector, H-3300) for heat-induced antigen retrieval, cooled to room temperature, and washed in Phosphate-Buffered Saline (PBS) (Invitrogen). The sections were incubated for 5 minutes in Dual Endogenous enzyme block (Dako) and 30 minutes in Protein block (Dako). SIV-Nef primary antibody (1:1500), as detailed in Table 2, was prepared in antibody diluent (Dako), and the sections were incubated for overnight at 4°C. Slides were washed three times with DPBS. Sections were incubated in polymer-based HRP-conjugated anti-mouse Dako EnVision system and developed with 3,3′-diaminobenzidine (DAB) chromogen. All paraffin-embedded sections were counterstained with Harris hematoxylin (Sigma). Controls included uninfected animals. Images were obtained with a Keyence, BZ-X710 microscope. Five images were taken per tissue per condition with 20x magnification and SIV-Nef staining was quantified using BZ-X analyzer software (Keyence). The average number per group was used for further statistical analysis.
Table 2. Primary and secondary antibodies used in the study.
Antibody | Source | Concentration | Secondary Antibody | Source | Fluorophore |
---|---|---|---|---|---|
Mouse anti-SIV-Nef | Thermofischer MA1-71522 | 1:1500 | polymer-based HRP-conjugated anti-mouse | Dako EnVision system/ Agilent | N/A |
Mouse anti-SIV-Nef | Thermofischer MA1-71522 | 1:1500 | Opal polymer HRP Ms+Rb | Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT | Opal 520 |
Mouse anti Neu-N | Millipore MAB377 | 1:1000 | Opal polymer HRP Ms+Rb | Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT | Opal 690 |
Rabbit Anti IBA-1 | Wako 019–19741 | 1:1000 | Opal polymer HRP Ms+Rb | Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT | Opal 690 |
Rabbit Anti- GFAP | Proteintech 23935-1-AP | 1:2000 | Opal polymer HRP Ms+Rb | Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT | Opal 570 |
Rabbit Anti- Cleaved Caspase 3 | Calbiochem 2923436) | 1:1500 | Opal polymer HRP Ms+Rb | Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT | Opal 690 |
Quantitative RNAscope in situ hybridization
SIV viral RNA was visualized using RNAscope on paraffin embedded tissues from hippocampus and cerebellum of SIVE, SIV+, and SIV+ART+ according to manufacturer’s protocols, using the SIVmac239 probe and RNAscope 2.5 HD Red Chromogenic Assay (Advanced Cellular Diagnostics, Newark, CA, cat #322360). Uninfected animals served as a negative control. Double labeling for SIV RNAscope followed by IHC staining for Nef protein, as previously reported [70, 71]. Slides were stained for anti-SIV-Nef. Sections were incubated in Polymer-based HRP-conjugated anti-mouse Dako EnVision system and developed with DAB chromogen. Sections were counterstained with hematoxylin, dried at 60°C, and mounted. Images were obtained with Keyence, BZ-X710 microscope and analyzed for colocalization of SIV viral RNA and SIV Nef protein. Five images were taken per tissue with 20x magnification and SIV-Nef staining was quantified using BZ-X analyzer software (Keyence). The average number per group was used for further statistical analysis.
Opal multiplex immunohistochemistry
Sections from hippocampus region of SIVE, SIV+, and SIV+ART+ macaques were deparaffinized and rehydrated through ethanol. Slides were treated for antigen unmasking using an AR6 buffer (Perkin Elmer) according to manufacturer’s guidelines (Microwave: 45 seconds, 100% power; 15 min, 20% power). Slides were allowed to cool for 30 min at room temperature and washed with 1X PBS. Slides were incubated for 10 min in blocking reagent, rinsed with 1X PBS, and incubated with the primary antibodies for one hour, as detailed in Table 2.
Slides were incubated with polymer HRP Ms + Rb for 10 min at room temperature. Opal dyes were diluted in amplification reagent (1:100) and slides were incubated in dyes for 10 minutes. Following development, slides were re-treated with AR6 buffer (Microwave: 45 seconds, 100% power; 15 min, 20% power) to strip slides of antibody complexes and allow consecutive staining without concern for antibody isotypes. Detection for each marker was completed before application of the next antibody. Slides were counterstained with spectral DAPI (Perkin Elmer) for 5 min at room temperature and washed with 1XPBST buffer and water. Coverslip slides were mounted using ProLong® Diamond Antifade Mountant (Thermofisher). All reagents are from Perkin Elmer, Opal™ 4-Color IHC Kit NEL810001KT. Images were obtained with Keyence, BZ-X710 microscope. Five images were taken per tissue with 20x magnification and SIV-Nef staining was quantified using BZ-X analyzer software (Keyence). The average number per group was used for further statistical analysis.
Statistical analysis
All statistics and graphical representations were done using GraphPad Prism version 8.0. Results are expressed as Mean +/- SEM. T-test was used in comparison of two unpaired groups. One-way ANOVA was used to compare three non-paired groups followed by a post-hoc Tukey HSD test. P value < 0.05 was considered significant.
Supporting information
(PDF)
Acknowledgments
The authors wish to thank past and present members of the Department of Neuroscience/Center for Neurovirology for sharing of reagents and ideas.
Data Availability
All relevant data are within the paper.
Funding Statement
This work was supported, in part, by grants awarded by the NIH to IKS and THB. This study utilized services offered by core facilities of the Comprehensive NeuroAIDS Center (CNAC NIMH Grant Number P30MH092177). SSY and JAR are supported by Interdisciplinary and Translational Research Training in NeuroAIDS (T32MH079785).
References
- 1.Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. The Lancet. 2013;382(9903):1525–33. 10.1016/S0140-6736(13)61809-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, et al. Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective. Science. 2014;343(6177):1243727–. 10.1126/science.1243727 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kearns A, Gordon J, Burdo TH, Qin X. HIV-1–Associated Atherosclerosis. Journal of the American College of Cardiology. 2017;69(25):3084–98. 10.1016/j.jacc.2017.05.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lohse N, Hansen A-BE, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival of Persons with and without HIV Infection in Denmark, 1995–2005. Annals of Internal Medicine. 2007;146(2):87 10.7326/0003-4819-146-2-200701160-00003 [DOI] [PubMed] [Google Scholar]
- 5.Sengupta S, Siliciano RF. Targeting the Latent Reservoir for HIV-1. Immunity. 2018;48(5):872–95. 10.1016/j.immuni.2018.04.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. Nature Reviews Neurology. 2016;12(4):234–48. 10.1038/nrneurol.2016.27 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunological Reviews. 2013;254(1):102–13. 10.1111/imr.12068 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Geyer M, Fackler OT, Peterlin BM. Structure–function relationships in HIV‐1 Nef. EMBO reports. 2001;2(7):580–5. 10.1093/embo-reports/kve141 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. The EMBO journal. 1992;11(8):3053–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Grzesiek S, Bax A, Clore GM, Gronenborn AM, Hu J-S, Kaufman J, et al. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nature structural biology. 1996;3(4):340–5. 10.1038/nsb0496-340 [DOI] [PubMed] [Google Scholar]
- 11.Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell. 1994;76(5):853–64. 10.1016/0092-8674(94)90360-3 [DOI] [PubMed] [Google Scholar]
- 12.Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature. 1991;350(6318):508–11. 10.1038/350508a0 [DOI] [PubMed] [Google Scholar]
- 13.Bandres JC, Ratner L. Human immunodeficiency virus type 1 Nef protein down-regulates transcription factors NF-kappa B and AP-1 in human T cells in vitro after T-cell receptor stimulation. Journal of Virology. 1994;68(5):3243–9. 10.1128/JVI.68.5.3243-3249.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ahmad N, Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science. 1988;241(4872):1481–5. 10.1126/science.3262235 [DOI] [PubMed] [Google Scholar]
- 15.Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. The New England Journal of Medicine. 1995;332(4):228–32. 10.1056/NEJM199501263320405 [DOI] [PubMed] [Google Scholar]
- 16.Chowers MY, Spina CA, Kwoh TJ, Fitch N, Richman DD, Guatelli JC. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. Journal of virology. 1994;68(5):2906–14. 10.1128/JVI.68.5.2906-2914.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Trillo-Pazos G, McFarlane-Abdulla E, Campbell IC, Pilkington GJ, Everall IP. Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. Brain Research. 2000;864(2):315–26. 10.1016/s0006-8993(00)02213-7 [DOI] [PubMed] [Google Scholar]
- 18.van Marle G, Henry S, Todoruk T, Sullivan A, Silva C, Rourke SB, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology. 2004;329(2):302–18. 10.1016/j.virol.2004.08.024 [DOI] [PubMed] [Google Scholar]
- 19.Thompson KA, Kent SJ, Gahan ME, Purcell DF, McLean CA, Preiss S, et al. Decreased Neurotropism of nef Long Terminal Repeat (nef /LTR)-Deleted Simian Immunodeficiency Virus. Journal of Neurovirology. 2003;9(4):442–51. 10.1080/13550280390218715 [DOI] [PubMed] [Google Scholar]
- 20.Chompre G, Cruz E, Maldonado L, Rivera-Amill V, Porter JT, Noel RJ. Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory. Neurobiology of Disease. 2013;49:128–36. 10.1016/j.nbd.2012.08.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Mordelet E, Kissa K, Cressant A, Gray F, Ozden S, Vidal C, et al. Histopathological and cognitive defects induced by Nef in the brain. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2004;18(15):1851–61. [DOI] [PubMed] [Google Scholar]
- 22.Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS (London, England). 1995;9(9):1001–8. 10.1097/00002030-199509000-00004 [DOI] [PubMed] [Google Scholar]
- 23.Fiala M, Singer EJ, Commins D, Mirzapoiazova T, Verin A, Espinosa A, et al. HIV-1 Antigens in Neurons of Cocaine-Abusing Patients. Open Virol J. 2008;2:24–31. 10.2174/1874357900802010024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Bergonzini V, Calistri A, Salata C, Del Vecchio C, Sartori E, Parolin C, et al. Nef and cell signaling transduction: a possible involvement in the pathogenesis of human immunodeficiency virus-associated dementia. Journal of Neurovirology. 2009;15(3):238–48. 10.1080/13550280902939748 [DOI] [PubMed] [Google Scholar]
- 25.Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. Journal of Virology. 1991;65(11):6094–100. 10.1128/JVI.65.11.6094-6100.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Gartner S, Markovits P, Markovitz D, Kaplan M, Gallo R, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233(4760):215–9. 10.1126/science.3014648 [DOI] [PubMed] [Google Scholar]
- 27.Pope M, Betjes MGH, Romani N, Hirmand H, Cameron PU, Hoffman L, et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell. 1994;78(3):389–98. 10.1016/0092-8674(94)90418-9 [DOI] [PubMed] [Google Scholar]
- 28.Koenig S, Gendelman H, Orenstein J, Dal Canto M, Pezeshkpour G, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089–93. 10.1126/science.3016903 [DOI] [PubMed] [Google Scholar]
- 29.Weissman D, Li Y, Orenstein JM, Fauci AS. Both a precursor and a mature population of dendritic cells can bind HIV. However, only the mature population that expresses CD80 can pass infection to unstimulated CD4+ T cells. Journal of Immunology (Baltimore, Md: 1950). 1995;155(8):4111–7. [PubMed] [Google Scholar]
- 30.Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotoxicity Research. 2005;8(1–2):119–34. 10.1007/BF03033824 [DOI] [PubMed] [Google Scholar]
- 31.Louboutin J-P, Agrawal L, Reyes BaS, van Bockstaele EJ, Strayer DS. Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases. Neuroscience. 2012;214:68–77. 10.1016/j.neuroscience.2012.03.061 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sabatier J, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. Journal of virology. 1991;65(2):961–7. 10.1128/JVI.65.2.961-967.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE, et al. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience. 2003;117(1):43–53. 10.1016/s0306-4522(02)00713-3 [DOI] [PubMed] [Google Scholar]
- 34.Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of Human Immunodeficiency Virus-1: Viral Proteins and Axonal Transport. Neurotoxicity Research. 2012;21(1):79–89. 10.1007/s12640-011-9279-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Alirezaei M, Watry DD, Flynn CF, Kiosses WB, Masliah E, Williams BRG, et al. Human immunodeficiency virus-1/surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signaling in neurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 2007;27(41):11047–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wang T., Green L. A., Gupta S. K., Kim C., Wang L., Almodovar S., et al. (2014). "Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction." PLoS One 9(3): e91063 10.1371/journal.pone.0091063 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.McNamara RP, Costantini LM, Myers TA, Schouest B, Maness NJ, Griffith JD, et al. Nef Secretion into Extracellular Vesicles or Exosomes Is Conserved across Human and Simian Immunodeficiency Viruses. mBio. 2018;9(1):e02344–17. 10.1128/mBio.02344-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Fujii Y, Otake K, Tashiro M, Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Letters. 1996;393(1):93–6. 10.1016/0014-5793(96)00859-9 [DOI] [PubMed] [Google Scholar]
- 39.Lenassi M, Cagney G, Liao M, Vaupotič T, Bartholomeeusen K, Cheng Y, et al. HIV Nef is Secreted in Exosomes and Triggers Apoptosis in Bystander CD4+ T Cells. Traffic. 2010;11(1):110–22. 10.1111/j.1600-0854.2009.01006.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Raymond A. D., Campbell-Sims T. C., Khan M., Lang M., Huang M. B., Bond V. C. et al. (2011). "HIV Type 1 Nef Is Released from Infected Cells in CD45 + Microvesicles and Is Present in the Plasma of HIV-Infected Individuals." AIDS Research and Human Retroviruses 27(2): 167–178. 10.1089/aid.2009.0170 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Khan M. B., Lang M. J., Huang M.-B., Raymond A., Bond V. C., Shiramizu B. et al. (2016). "Nef exosomes isolated from the plasma of individuals with HIV-associated dementia (HAD) can induce Aβ1–42 secretion in SH-SY5Y neural cells." Journal of NeuroVirology 22(2): 179–190. 10.1007/s13365-015-0383-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ferdin J., Goričar K., Dolžan V., Plemenitaš A., Martin J. N., Peterlin B. M., et al. (2018). "Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA." PloS one 13(1): e0191613 10.1371/journal.pone.0191613 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Qiao X., He B., Chiu A., Knowles D. M., Chadburn A. and Cerutti A. (2006). "Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells." Nature Immunology 7(3): 302–310 10.1038/ni1302 [DOI] [PubMed] [Google Scholar]
- 44.Hudson L, Sprent J (1976) Specific adsorption of IgM antibody onto H-2-activated mouse T lymphocytes The Journal of experimental medicine 143:444–449 10.1084/jem.143.2.444 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Hudson L, Sprent J, Miller J, Playfair J (1974) B cell-derived immunoglobulin on activated mouse T lymphocytes Nature 251:60–62 10.1038/251060a0 [DOI] [PubMed] [Google Scholar]
- 46.Joly E, Hudrisier D (2003) What is trogocytosis and what is its purpose? Nature immunology 4:815–815 10.1038/ni0903-815 [DOI] [PubMed] [Google Scholar]
- 47.Dupont M, Souriant S, Lugo-Villarino G, Maridonneau-Parini I, Vérollet C (2018) Tunneling nanotubes: intimate communication between myeloid cells Frontiers in immunology 9:43 10.3389/fimmu.2018.00043 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Théry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function Nature reviews immunology 2:569–579 10.1038/nri855 [DOI] [PubMed] [Google Scholar]
- 49.Chung-ha OD et al. (2014) Transcellular degradation of axonal mitochondria Proceedings of the National Academy of Sciences 111:9633–9638 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Fitzner D et al. (2011) Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis Journal of Cell Science 124:447–458 10.1242/jcs.074088 [DOI] [PubMed] [Google Scholar]
- 51.Frühbeis C et al. (2013) Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte–neuron communication PLoS Biol 11:e1001604 10.1371/journal.pbio.1001604 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Hayakawa K et al. (2016) Transfer of mitochondria from astrocytes to neurons after stroke Nature 535:551–555 10.1038/nature18928 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Chistiakov DA, Chistiakov AA (2017) α-Synuclein-carrying extracellular vesicles in Parkinson’s disease: deadly transmitters Acta Neurologica Belgica 117:43–51 10.1007/s13760-016-0679-1 [DOI] [PubMed] [Google Scholar]
- 54.Kalra H, Drummen GP, Mathivanan S (2016) Focus on extracellular vesicles: introducing the next small big thing International journal of molecular sciences 17:170 10.3390/ijms17020170 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, et al. (2006) Alzheimer's disease β-amyloid peptides are released in association with exosomes Proceedings of the National Academy of Sciences 103:11172–11177 10.1073/pnas.0603838103 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Vella LJ, Hill AF, Cheng L (2016) Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer’s and Parkinson’s disease International journal of molecular sciences 17:173 10.3390/ijms17020173 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Muratori C et al. (2009) Massive Secretion by T Cells Is Caused by HIV Nef in Infected Cells and by Nef Transfer to Bystander Cells Cell Host & Microbe 6:218–230 10.1016/j.chom.2009.06.009 [DOI] [PubMed] [Google Scholar]
- 58.Hashimoto M et al. (2016) Potential role of the formation of tunneling nanotubes in HIV-1 spread in macrophages The Journal of Immunology 196:1832–1841 10.4049/jimmunol.1500845 [DOI] [PubMed] [Google Scholar]
- 59.Uhl J, Gujarathi S, Waheed AA, Gordon A, Freed EO, Gousset K (2019) Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes Journal of cell communication and signaling 13:209–224 10.1007/s12079-018-0493-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol. 2009;10(9):1008–17. 10.1038/ni.1753 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Park I-W, Fan Y, Luo X, Ryou M-G, Liu J, Green L, et al. (2014) HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication PloS one 9:e99545 10.1371/journal.pone.0099545 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Pužar Dominkuš P, Ferdin J, Plemenitaš A, Peterlin BM, Lenassi M (2017) Nef is secreted in exosomes from Nef.GFP-expressing and HIV-1-infected human astrocytes Journal of NeuroVirology 23:713–724 10.1007/s13365-017-0552-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Campbell TD, Khan M, Huang M-B, Bond VC, Powell MD. HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Ethnicity & Disease. 2008;18(2 Suppl 2):S2-14–9. [PMC free article] [PubMed] [Google Scholar]
- 64.Mukhamedova N, Hoang A, Dragoljevic D, Dubrovsky L, Pushkarsky T, Low H, et al. Exosomes Containing HIV Protein Nef Reorganize Lipid Rafts Potentiating Inflammatory Response in Bystander Cell PLoS Pathog. 2019. July 25;15(7):e1007907 10.1371/journal.ppat.1007907 eCollection 2019 Jul. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Raymond AD, Diaz P, Chevelon S, Agudelo M, Yndart-Arias A, Ding H, et al. Microglia-derived HIV Nef+ Exosome Impairment of the Blood-Brain Barrier Is Treatable by Nanomedicine-Based Delivery of Nef Peptides. J Neurovirol. 2016. April;22(2):129–39. 10.1007/s13365-015-0397-0 Epub 2015 Dec 2. [DOI] [PubMed] [Google Scholar]
- 66.Pleet ML, Branscome H, DeMarino C, Pinto DO, Zadeh MA, Rodriguez M, et al. Autophagy, EVs, and Infections: A Perfect Question for a Perfect Time. Front Cell Infect Microbiol. 2018. October 18;8:362 10.3389/fcimb.2018.00362 eCollection 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Saribas AS, Cicalese S, Ahooyi TM, Khalili K, Amini S, Sariyer IK. HIV-1 Nef is released in extracellular vesicles derived from astrocytes: evidence for Nef-mediated neurotoxicity. Cell Death & Disease. 2018;8(1):e2542–e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Groups ftCaH Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology. 2011;17(1):3–16. 10.1007/s13365-010-0006-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, Hagiwara Y, et al. Vpr in Plasma of HIV Type 1-Positive Patients Is Correlated with The HIV Type 1 RNA Titers. AIDS Research and Human Retroviruses. 2007;23(3):391–7. 10.1089/aid.2006.0124 [DOI] [PubMed] [Google Scholar]
- 70.Nowlin BT, Burdo TH, Midkiff CC, Salemi M, Alvarez X, Williams KC. SIV Encephalitis Lesions Are Composed of CD163+ Macrophages Present in the Central Nervous System during Early SIV Infection and SIV-Positive Macrophages Recruited Terminally with AIDS. The American Journal of Pathology. 2015;185(6):1649–65. 10.1016/j.ajpath.2015.01.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Sariyer IK, Gordon J, Burdo TH, Wollebo HS, Gianti E, Donadoni M, et al. Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine. Molecular Therapy. 2019;27(12):2067–79. 10.1016/j.ymthe.2019.10.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
(PDF)
Data Availability Statement
All relevant data are within the paper.